Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study

Table 1 Demographic and clinical characteristics of study patients

Characteristics	Values^a (n = 49)
Age (yr)	11.5 (4–17)
Sex [females, n (%)]	33 (67.3 %)
Weight (kg)	41 (13.4–119.7)
Height (cm)	146 (95–178)
MTX weekly dose (mg)	13.75 (7.5–20)
MTX weekly dose (mg/kg)	0.31 (0.08–0.67)
MTX weekly dose (mg/m²)^b	10.2 (4.1–15.5)
Number of medications prescribed	5 (1–8)
Number of side effects recorded	3 (1–2)
Pain scale^c	0.9 (0–7.1)
General evaluation scale^c	0.5 (0–8.2)
CMAS score^d	51.5 (42–55)

^aValues represent median (range), except where indicated otherwise
^bSurface area was calculated using the Mosteller method [59]
^cPain scale and general evaluation scores were obtained from the patients’ Childhood Health Assessment Questionnaire
^dChildhood Myositis Assessment Scale (CMAS) score was recorded for children with JDM